BRAF and melanoma: In contrast, melanoma cell cultures Me_cc111 and Me_cc128, with a cross-susceptible phenotype, were isolated from patients who subsequently (75.4 and 2.8 months, after Me_cc111 and Me_cc128 isolation, respectively) were treated with the association of a BRAF and a MEK inhibitor or in monotherapy with a MEK inhibitor and experienced a partial response or a complete response, respectively.